Welcome to our dedicated page for CREATIVE MEDICAL TECHNOLOGY HOLDINGS SEC filings (Ticker: CELZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CREATIVE MEDICAL TECHNOLOGY HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CREATIVE MEDICAL TECHNOLOGY HOLDINGS's regulatory disclosures and financial reporting.
Creative Medical Technology Holdings, Inc. reported no revenue for the quarter ended June 30, 2026 and a net loss of $1.5 million, compared with a $1.2 million loss a year earlier. For the first six months of 2026, the net loss was $2.9 million, similar to the prior‑year period, as the company continued to fund clinical development and corporate operations.
Research and development expenses were $459,200 for the quarter and $1.0 million year‑to‑date, lower than 2025 as the CELZ‑201 ADAPT trial moved from recruitment and dosing to follow‑up. Selling, general and administrative expenses increased to $1.1 million for the quarter and $2.0 million year‑to‑date, driven by marketing, salaries, legal and travel.
Cash and equivalents were $8.7 million at June 30, 2026, up from $7.2 million at year‑end, supported by $4.5 million of proceeds from June warrant exercises, leaving working capital of about $8.3 million. The company highlighted progress on its regenerative platforms, including the Olastrocel™ (CELZ‑201) Phase 1/2 ADAPT trial with FDA Fast Track designation, Ultrasome™ pilot data in knee osteoarthritis, and the CELZ Biodefense Project PHOENIX burn‑pit registry.
Creative Medical Technology Holdings, Inc. is registering for resale up to 5,580,680 shares of common stock issuable upon exercise of privately placed warrants held by selling stockholders. The company is not selling any shares and will not receive proceeds from stockholder resales, though it may receive cash from warrant exercises.
The registration could increase tradable float, while total common shares would be 12,173,237 if all warrants are exercised, versus 6,592,557 outstanding prior to the offering. The company highlights progress in its cell-therapy pipeline, including positive data from StemSpine®, CELZ-001 and CELZ-201 studies, FDA Orphan Drug Designation for ImmCelz™ in Brittle Type 1 Diabetes, and Fast Track designation for CELZ-201-DDT. Interim safety reviews have supported continuation of clinical trials, and several AI-enabled collaborations aim to advance its iPSC platforms.
Creative Medical Technology Holdings, Inc. has filed a Form S-3 registration statement covering the resale of up to 5,580,680 shares of common stock, par value $0.001 per share. These shares are issuable upon exercise of common stock purchase warrants (Inducement Warrants) issued on June 30, 2026 in a private placement to the selling stockholders named in the prospectus.
The company is not selling any shares in this offering and will not receive proceeds from resales by the selling stockholders. It will receive cash only if the warrants are exercised, which would be used for working capital and general corporate purposes. Shares outstanding were 6,592,557 before warrant exercise and would be 12,173,237 assuming full exercise. The common stock trades on the Nasdaq Capital Market under the symbol CELZ, with a last reported price of $0.81 per share on July 23, 2026.
The filing highlights that large resales or the perception of potential sales could pressure the stock price. Two institutional holders, including Armistice Capital Master Fund Ltd. and Hudson Bay Master Fund Ltd., hold the Inducement Warrants, which are subject to a 4.99% beneficial ownership limitation. The company also summarizes recent clinical and regulatory milestones across its ImmCelz™, AlloStem™, StemSpine® and iPSC-based platforms, including Orphan Drug Designation, FDA trial clearances, Fast Track designation for CELZ-201-DDT, and AI-enabled collaborations.
Creative Medical Technology Holdings, Inc. is calling a special stockholder meeting on August 28, 2026 to vote on two capital-structure proposals. The first would amend its Articles of Incorporation to increase authorized common stock from 25,000,000 to 100,000,000 shares, giving flexibility for future capital raising, equity incentives, strategic relationships, or acquisitions, while acknowledging potential dilution and anti-takeover effects.
The second proposal seeks approval for the exercise in full of private-placement Investor Warrants to purchase 5,580,680 shares of common stock at $1.60 per share. Because exercising these warrants would issue more than 20% of currently outstanding shares, Nasdaq Listing Rule 5635(d) requires stockholder approval, and company agreements obligate repeated meetings every 60 days until approval is obtained. As of June 30, 2026, common shares outstanding were 4,741,236, with warrants and options for an additional 10,633,425 shares.
Creative Medical Technology Holdings entered into warrant exercise inducement letters, prompting holders of warrants for 2,790,340 shares to exercise at $1.60 per share, generating approximately $4.5 million in gross proceeds. In return, the company reduced the original $2.86 exercise price and issued new Inducement Warrants for 5,580,680 shares at $1.60 per share.
The Inducement Warrants were issued in a private placement, will become exercisable only after required stockholder approval and then remain exercisable for five years. The company plans to file a resale registration statement on Form S-3 within thirty days. Roth Capital Partners will receive an 8% advisory fee on gross proceeds plus $50,000 for legal expenses. Separately, the compensation committee approved a $100,000 bonus for CEO Timothy Warbington.
Creative Medical Technology Holdings, Inc. is asking stockholders at a Special Meeting to approve two proposals: (1) amend the Articles of Incorporation to increase authorized Common Stock from 25,000,000 shares to 100,000,000 shares; and (2) approve the exercise in full of 5,580,680 Investor Warrants at $1.60 per share. The record date for voting was June 30, 2026, when 4,741,838 shares were outstanding. The Board unanimously recommends a FOR vote on both proposals.
Creative Medical Technology Holdings, Inc. is registering 3,045,685 shares of common stock, 6,091,371 Public Warrants, 3,045,685 pre-funded warrants, and up to 9,137,056 shares of common stock underlying those warrants in a best efforts public offering. The assumed combined public offering price is $1.97 per share and accompanying Public Warrants, implying estimated net proceeds of about $5.34 million. Common shares outstanding would rise from 3,696,668 to 6,742,353 if only shares (and no pre-funded warrants) are sold, before any warrant exercises, creating immediate dilution of $0.37 per share for new investors. Pro forma cash would increase from $5.72 million to $11.06 million as of March 31 2026. The company plans to use proceeds mainly to advance its AlloStemSpine® back pain trial (CELZ‑201‑DDT ADAPT), Type 1 diabetes study (CELZ‑201 CREATE‑1), its IPScelz™ iPSC program with Greenstone, other pipeline work, and general corporate purposes.
Creative Medical Technology Holdings is conducting a best efforts public offering of up to 3,045,685 shares of common stock, warrants to purchase up to 6,091,371 shares, pre-funded warrants to purchase up to 3,045,685 shares, and up to 9,137,056 shares underlying those warrants.
The assumed combined offering price is $1.97 per share and accompanying warrants, implying estimated net proceeds of about $5.34 million, which the company plans to use primarily to advance multiple CELZ-201 and CELZ-001 clinical programs, its IPScelz™ platform, and for working capital. Shares outstanding would rise from 3,696,668 to 6,742,353 if the full common stock amount is sold.